Laboratory assessment of the anticaries potential of a new dentifrice.
OBJECTIVE
The aim of the present study was to investigate the anticaries potential of a new sodium fluoride dentifrice in comparison to two commercial dentifrices containing different fluoride compounds by determining enamel fluoride uptake (EFU) and early caries lesion remineralization (REM) in an established in vitro caries remineralization/demineralization pH cycling model.


METHODS
Test products were: new dentifrice formulation in a fluoride dose-response (0; 675; 1426 ppm F as sodium fluoride [NaF-0; NaF-675; NaF]); Elmex Kariesschutz (1400 ppm F as amine fluoride [AmF]); and Oral-B Pro-Expert (1450 ppm F-1100 ppm F as stannous fluoride and 350 ppm F as sodium fluoride [SnNaF]). Artificial caries-like lesions were formed in human enamel specimens by immersion in lactic acid buffer (LA). Specimens were then subjected to a daily cycling regime for 20 days comprising four one-minute dentifrice slurry treatments (prepared in pooled human saliva), and one four-hour LA challenge and remineralization in pooled human saliva. After 20 days, REM was evaluated as the change in surface Vickers microhardness from lesion baseline and EFU using the microdrill technique. The data were analyzed using ANOVA.


RESULTS
A good fluoride dose-response was established for EFU and REM, with NaF delivering greater EFU and REM than NaF-675, which was superior to NaF-0 (p < 0.05). The new dentifrice NaF also showed greater EFU and REM than AmF and SnNaF (p < 0.05). In EFU, AmF and SnNaF were as efficacious as NaF-675 and superior to NaF-0 (p < 0.05). AmF and NaF-675 were also comparable in REM, whereas both products exhibited superior REM vs. SnNaF (p < 0.05), which was superior to NaF-0 (p < 0.05).


CONCLUSIONS
The present study has demonstrated that fluoride dentifrices vary in their capability of enhancing anticaries potential as determined using an established in vitro caries cycling model. The new dentifrice NaF showed superior predicted anticaries potential compared to the two commercial dentifrices AmF and SnNaF in this model, which demonstrates the importance of fluoride compound and formulation excipients on driving anticaries potential in vitro.
Lippert
Frank
F
GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey, UK. frank.x.lippert@gsk.com
Newby
Evelyn E
EE
Lynch
Richard J M
RJ
Chauhan
Vijeash K
VK
Schemehorn
Bruce R
BR
D000588:Amines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002327:Cariostatic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003743:Dental Enamel / Q000378:metabolism; D003802:Dentifrices / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003959:Diamines; D004338:Drug Combinations; D005459:Fluorides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D012463:Saliva; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014002:Tin Fluorides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017001:Tooth Demineralization / Q000188:drug therapy; D014089:Tooth Remineralization / Q000379:methods
D000588:Amines; D002327:Cariostatic Agents; D003802:Dentifrices; D003959:Diamines; D004338:Drug Combinations; D014002:Tin Fluorides; C495399:Olaflur; D012969:Sodium Fluoride; D005459:Fluorides